[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cormedix Inc (CRMD)

Cormedix Inc (CRMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 586,551
  • Shares Outstanding, K 79,050
  • Annual Sales, $ 311,710 K
  • Annual Income, $ 163,060 K
  • EBIT $ 150 M
  • EBITDA $ 166 M
  • 60-Month Beta 1.41
  • Price/Sales 1.86
  • Price/Cash Flow 3.58
  • Price/Book 1.42

Options Overview Details

View History
  • Implied Volatility 83.72% (-11.97%)
  • Historical Volatility 28.32%
  • IV Percentile 74%
  • IV Rank 48.64%
  • IV High 126.72% on 07/09/25
  • IV Low 42.99% on 08/15/25
  • Expected Move (DTE 18) 1.16 (15.18%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 950
  • Volume Avg (30-Day) 894
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 65,513
  • Open Int (30-Day) 64,891
  • Expected Range 6.51 to 8.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.45
  • Number of Estimates 2
  • High Estimate $0.53
  • Low Estimate $0.38
  • Prior Year $0.30
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.56 +16.78%
on 03/30/26
7.74 -1.02%
on 04/27/26
+0.95 (+14.17%)
since 03/27/26
3-Month
6.13 +25.08%
on 03/06/26
8.53 -10.19%
on 02/02/26
-0.09 (-1.15%)
since 01/27/26
52-Week
6.13 +25.08%
on 03/06/26
17.43 -56.05%
on 06/23/25
-1.44 (-15.81%)
since 04/25/25

Most Recent Stories

More News
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 – – Study showed favorable benefit for toxicity related discontinuations...

CRMD : 7.59 (+2.29%)
CorMedix to Participate in Needham Virtual Healthcare Conference

PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.59 (+2.29%)
CorMedix: Q4 Earnings Snapshot

CorMedix: Q4 Earnings Snapshot

CRMD : 7.59 (+2.29%)
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒    ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒...

CRMD : 7.59 (+2.29%)
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.59 (+2.29%)
CorMedix to Participate in Upcoming Investor Conferences

BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.59 (+2.29%)
CorMedix Therapeutics Announces Share Repurchase Program

BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.59 (+2.29%)
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.59 (+2.29%)
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026

2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.

EVMN : 25.10 (-1.10%)
ATAI : 4.44 (-4.10%)
CRMD : 7.59 (+2.29%)
Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud Investigation

New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into CorMedix Inc. ("CorMedix Inc.") (NASDAQ: CRMD) concerning potential...

CRMD : 7.59 (+2.29%)

Business Summary

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed...

See More

Key Turning Points

3rd Resistance Point 7.64
2nd Resistance Point 7.54
1st Resistance Point 7.48
Last Price 7.59
1st Support Level 7.32
2nd Support Level 7.21
3rd Support Level 7.15

See More

52-Week High 17.43
Fibonacci 61.8% 13.11
Fibonacci 50% 11.78
Fibonacci 38.2% 10.44
Last Price 7.59
52-Week Low 6.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.